viernes, 4 de septiembre de 2015

Cinema Paradiso: Orgasm Inc. / Liz Canner



Despues de la reciente aprobación y acontecimientos con Addyi debería ser el film del otoño (o de l@s FSD otoñales...)

Liz Canner’s Orgasm, Inc. introduces us to the one of the latest composed diseases: Female Sexual Dysfunction (FSD). Canner tells stories of people working hard to create and treat the disease, as well those fighting this dehumanizing and damaging initiative. Hundreds of billions of dollars and the welfare of countless women are at stake in this war between people and the medical-industrial complex. 

Aside from Canner herself, the most dramatic hero is Leonore Tiefer, Ph.D., a sex therapist and professor of psychiatry at New York University School of Medicine, who’s created an organization to fight the medicalization of sex via her New View Campaign, and has published a book entitled A New View of Women’s Sexual Problems. Tiefer figures prominently in the climatic scene of an FDA advisory panel hearing on a Procter & Gamble application for an FSD treatment. 

 Canner also covers the emergence of cosmetic female genital mutilation – with the magnificent euphemistic label of ‘vaginal rejuvenation.’ There are over 300 clinics around the world providing this service – and their clients include teenagers. 

If you find it hard to subscribe to the idea that 43% of American women have a disease called Female Sexual Dysfunction and are, therefore, in need of medical treatment, and if you want to make a difference, rent or buy Orgasm, Inc. I’m sure you’ll find yourself sharing it with your friends. 


Oh, and by the way, if you thought the Orgasmatron was just a figment of Woody Allen’s imagination we experienced in his classic Sleeper, you’ve got another thing comin’.

 www.orgasminc.org

Ver también:

"Orgasmos interruptus" de VIVUS o...de vivos.


 

Recordar, con Boehringer, era...descartar flibanserin.

Ver:

Boehringer (flibanserin) "no funciona" con las mujeres...

BOEHRINGER INGELHEIM: Las mujeres se van a quedar con las ganas...

C(r)O_ño...con la CRO*: "orgasmos (datos) fingidos" para Boehringer Ing.

VIAGRA: La pildorita rosa...destiñe, Guadalupe Treibel


Todo esto publicamos en su momento...

jueves, 3 de septiembre de 2015

A confesión de parte...: Martín Caicoya*, ex Director Médico HUCA


"Los médicos estamos acostumbrados a recibir financiación de la industria farmacéutica, tanto para la asistencia a congresos como para la investigación. 
Son actividades que en principio no buscan el lucro personal sino la mejora de la atención. Sin embargo, tienen un efecto perverso inevitable. 

Aunque no conozco a ningún médico que sienta que la aceptación de dinero de la industria afecte a sus elecciones, es inevitable que a la hora de tomar una decisión, cuando existe esa opción, se inclinarán por la que complace a la industria que los financia; y el examen de los datos de un estudio estará condicionado por el financiador, que celebrará los resultados si le son favorables con más apoyo."

(Más)

Ver también:

Citario / El dijo que...: Edelmiro Menendez, Presidente de la Sociedad Española de Diabetes y el "sponsorismo" de la industria farmacéutica.

Gifts and money influence physician prescribing

España: Los pagos a los médicos serán públicos


(*) Martín Caicoya G. es doctor en Medicina por la Universidad de Salamanca, especialista en Medicina Interna y máster en Salud Pública por la Universidad de Columbia. Fue jefe de prevención de Riesgos Laborales de la Administración del Principado y Director médico en el HUCA)

Es tiempo de comprar AstraZeneca?



Summary 

  • Astra stock has declined due to patent expirations and generic competition. 

  • Astra revenues are likely to continue to decline. 

  • However, Astra has an extremely high potential pipeline of oncology drugs. 

  • Moreover, Astra maintains a solid financial position. 

  • I believe that Astra is poised for a rebound in 2016, and that a well-time investment in Astra could prove lucrative as a result.
Ver

  
Cancer remains one of the major causes of death in the developed world. One in four people are expected to die from the disease, and half of us must face up to suffering from some form of cancer during our lives. 

 Yet hopes for a cure – or at least a better chance of recovery – have emerged from an American cancer conference. 

Hailed as a once-in-a-generation advance in treatment, so-called immunotherapies aim to harness the patient’s own immune system to help fight cancer.


Its is good news for patients. The developments also have the potential to give a major boost to Britain’s quoted pharmaceutical companies. And it couldn’t have come at a better time for FTSE 100-listed AstraZeneca

A central plank of the company’s strategy is to develop novel combinations of drugs that target the escape mechanisms cancers use to evade the body’s immune system. 

 Oncology – cancer treatment – is a key therapeutic area in which Astra has expertise and which it hopes could transform the business.

By 2020 the group is aiming to bring six new cancer medicines to patients, focusing on ovarian, lung, breast and blood cancers. 

Last year when Astra was fighting off a predatory £69billion bid from US rival Pfizer, chief executive Pascal Soriot warned that one of the costs of combining the two firms could be delays to its development pipeline of potential cancer treatments.

Ver:

Pfizer y AstraZeneca: Son rumores? (y de otros mergers...)


Since the deal collapsed, investors have been waiting for Astra’s share price to come nearer to the £55-a-share Pfizer offer. Soriot remains under pressure to justify the board’s rejection of the deal. Immunotherapy, therefore, could be the answer. 

 Decision Resources Group analyst Khurram Nawaz said: ‘Cancer immunotherapy is one of the most exciting fields of research in oncology, and successful drug development in this space offers a highly lucrative opportunity for drug developers.’ 

Más

miércoles, 2 de septiembre de 2015

GSK y otr@s...(Pfizer, Roche, Novartis, Sandoz, Teva...) ahora "Corrupción a la Romania..."


Drugmaker GlaxoSmithKline, which was fined a record 3 billion yuan ($483 million) for corruption in China last year and is examining possible staff misconduct elsewhere, faces new allegations of bribery in Romania. 

Ver:

GLAXO: Sex, drugs and videotape en China. / Project Scorpion


 GSK confirmed it was looking into the latest claims of improper payments set out in a whistleblower's email sent to its top management on Monday. A copy of the email was seen by Reuters. 

The company is already probing alleged bribery in Poland, the United Arab Emirates, Lebanon, Jordan, Syria and Iraq.

Ver:

GLAXO "soborna" de nuevo...ahora Polonia, Jordania, Líbano...


The latest allegations say GSK paid Romanian doctors hundreds, and in one cases thousands, of euros between 2009 and 2012 for prescribing its medicines, including prostate treatments Avodart and Duodart and Parkinson's disease drug Requip

According to the email, the doctors were notionally paid for speaking engagements, but in three out of six cases, including the most highly paid one, they did not give any speech. The other three medics gave only one speech each, despite receiving multiple payments. 

GSK also provided doctors with many international trips and made payments to them under the guise of participation in advisory boards, the email said. 

The company said it would look "very thoroughly" into the claims, which cover a period before its pledge in December 2013 to stop paying doctors to speak on its behalf or to attend international conferences. 

 “We do receive letters of this sort from time to time. We welcome and support the opportunity for people to speak up if they have any concerns," GSK said in a statement. "Sometimes we do find things and we act on it; sometimes our findings do not substantiate the matters being raised." 

The China scandal, which involved alleged bribes totaling hundreds of millions of dollars, hit GSK's sales in the country, although Chief Executive Andrew Witty, reporting quarterly results on Wednesday, said its Chinese business was stabilizing. 

The sender of the Romania email said its contents would be passed on to the U.S. Department of Justice and the Securities and Exchange Commission (SEC), which are investigating GSK for possible breaches of the Foreign Corrupt Practices Act. 

An SEC program provides cash incentives for whistleblowers to report corporate malpractice. 

 (Editing by Jane Barrett and David Holmes)

Y otr@s...Pfizer, Roche, Novartis, Teva...

Romanian authorities are investigating 11 pharma companies under suspicion of bribing doctors to prescribe cancer drugs in the country. 

Among these companies was Roche, which has confirmed that its offices were searched and that it is cooperating fully with the authorities. (Más




The National Anticorruption Directorate – DNA’s investigation on deals between Romanian doctors and drug companies for cancer drug prescriptions might target 11 of the largest pharmaceutical companies in the local market. 

The list includes Roche Romania, subsidiary of Swiss multinational Roche, as well as Actavis, Pfizer Romania, Teva Pharmaceuticals Romania, Novartis Pharma Services, Alvogen Romania, Sandoz Pharma Services, Glaxosmithkline Romania, Egis Internațional, drug distributor Romastru Trading and drug producer Glenmark Pharmaceuticals, according to judicial sources quoted by Agerpres. (Más)

Companies paid for the doctors’ travels to international medical conventions as well as leisure trips to other countries. In 2014, a pharma company paid almost EUR 1 million to a tourism operator, as a “sponsorship” for doctors, which, in fact, was a bribe, according to judicial sources. Companies paid for doctors’ trips to San Diego, Las Vegas, and Paris, among others. The trips included visits to the Grand Canyon and hotel stays at the Bellagio in Las Vegas. 

In return, the investigated doctors prescribed the drugs produced or distributed by these companies, instead of generic drugs, which are cheaper, but have similar effects. The scheme also artificially increased the number of patients who benefited from these expensive treatments and created unjustifiably high inventories of such drugs in some public hospitals, which damaged the National Social Health Insurance Fund, according to judicial sources, quoted by Mediafax. (Más)

FDA aprueba el primer "3D Printed Drug Product"

La Agencia de Alimentos y Medicamentos (FDA por sus siglas en inglés) de Estados Unidos aprobó una medicina contra la epilepsia llamada Spritam; dicho medicamento se hace por medio de impresoras 3D y es el primero en su género que ha sido aceptado por la FDA. 

La empresa que fabricó el Spritam (Aprecia) lanzó al mercado, lo que sería hasta ahora, el único medicamento impreso que puede ser ingerido por personas. 

La realización del producto fue posible gracias a que las maquinas imprimieron capas del fármaco en polvo (método utilizado por las impresoras 3D). La estructura del medicamento es única, se disuelve fácilmente a comparación de otras píldoras además de tener un tamaño más pequeño. 

De acuerdo con los especialistas, esta pastilla será de utilidad para los médicos, ya que las dosis de medicamento se determinará en el tamaño de ésta, lo que permite recetar el medicamento según la edad del paciente. (Más)


Aprecia Pharmaceuticals Company has announced that the FDA has approved Spritam levetiracetam for oral use as a prescription adjunctive therapy in the treatment of partial onset seizures, myoclonic seizures and primary generalized tonic-clonic seizures in adults and children with epilepsy. 


Spritam utilizes Aprecia’s proprietary ZipDose Technology platform, a groundbreaking advance that uses three-dimensional printing (3DP) to produce a porous formulation that rapidly disintegrates with a sip of liquid. While 3DP has been used previously to manufacture medical devices, this approval marks the first time a drug product manufactured with this technology has been approved by the FDA

By combining 3DP technology with a highly-prescribed epilepsy treatment, Spritam is designed to fill a need for patients who struggle with their current medication experience,” said Don Wetherhold, CEO of Aprecia. “This is the first in a line of central nervous system products Aprecia plans to introduce as part of our commitment to transform the way patients experience taking medication.” 

ZipDose Technology enables the delivery of a high drug load, up to 1000 mg in a single dose. As a result, Spritam enhances the patient experience — administration of even the largest strengths of levetiracetam with just a sip of liquid. In addition, with Spritam there is no measuring required as each dose is individually packaged, making it easy to carry this treatment on the go. Spritam is expected to be available in the first quarter of 2016. 

In my experience, patients and caregivers often have difficulty following a treatment regimen. Whether they are dealing with a swallowing disorder or the daily struggle of getting a child to take his or her medication, adherence can be a challenge,” said Marvin H. Rorick III, neurologist at Riverhills Neuroscience in Cincinnati, Ohio. “Especially for children and seniors, having an option for patients to take their medication as prescribed is important to managing this disease.” (Más)

domingo, 30 de agosto de 2015

Muere Oliver Sacks, explorador de la mente y la tolerancia.

Oliver Sacks, el neurólogo más prestigioso del mundo, ha muerto de cáncer a los 82 años, informa The New Yok Times. El pasado mes de febrero, Sacks anunció en esta misma publicación que padecía un cáncer terminal.


 

"No puedo fingir que no tenga miedo. Pero mi sentimiento predominante es la gratitud. He amado y he sido amado; he recibido mucho y he puesto algo de mi parte; he leído y viajado y pensado y escrito...", decía en un artículo titulado 'Mi propia vida'. 

Años antes, el neurólogo y escritor, autor de 'Despertares' y 'Un antropólogo en Marte', ya había padecido la enfermedad, que le costó la visión de uno de sus ojos. La enfermedad se volvió después letal. 

 Como médico y escritor, Oliver Sacks alcanzó un nivel de popularidad poco común entre los científicos, lo que le permitió vender más de un millón de ejemplares sólo en Estado Unidos e incluso su obra 'Despertares' (1973) sobre un grupo de enfermos con casos raros de encefalitis fue llevada en 1990 al cine y protagonizada por Robin Williams y Robert De Niro. (...) 

Tal ha sido su capacidad para transmitir los problemas del cerebro, que muchos especialistas reconocen que eran seguidores de sus artículos y libros. "Leía su artículos en The New York Times. El último que leí fue uno sobre la memoria y en él hacía algo que ha hecho a lo largo de su obra, utilizarse como ejemplo de lo que escribía. Ese era otro rasgo que le hacía más fuerte, porque al mostrar su vulnerabilidad, como hizo en su libro llamado Migraña (donde contaba ciertos síntomas que él tenía porque sufría de migrañas), empatizaba más con el lector", afirma Patricia Pozo Rosich, neuróloga de la Unidad de Cefalea del Hospital Universitario Vall d'Hebron de Barcelona. (Más)

Ver también: 
Muere Oliver Sacks, explorador de la mente y la tolerancia


Will Sprout's little pink pill open Pandora's Box!? (video)


WASHINGTON, DC — 
The first prescription pill to treat low sexual desire in women was finally approved by the U.S. Food and Drug Administration on Tuesday. 

 The little pink pill will be sold under the brand name Addyi and manufactured by Sprout Pharmaceuticals, a privately held company. It will only be available through certified and specially trained healthcare professionals and pharmacies due to its potentially dangerous side effects. 

Addyi, whose generic name is flibanserin, is designed to help women get their groove back. The pill is designed for premenopausal women who suffer from hypoactive sexual desire disorder (HSDD). 

The FDA rejected flibanserin twice in the past, but finally caved after a heavy lobbying campaign by Sprout and women's groups. 

Women who took Addyi in a clinical study had an increase of about one orgasm a month, so that means a whopping 12 extra orgasms a year. Only problem is you need to take Addyi every day. 

Addyi can cause low blood pressure, fainting, nausea, dizziness, sleepiness and shouldn't be taken with booze, but otherwise it's completely safe.